Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
about
Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancerGlucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetesCombined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell LineSitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes.An updated review on cancer risk associated with incretin mimetics and enhancers.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.Exendin-4 Exhibits Enhanced Anti-tumor Effects in Diabetic Mice.The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer.Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells.Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.Impact of metabolic disorders on prostate cancer growth: Androgen and insulin resistance perspectives.The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis.Exendin-4 does not modify growth or apoptosis of human colon cancer cells.Glucagon promotes colon cancer cell growth via regulating AMPK and MAPK pathways.
P2860
Q28068998-7FCCCC90-4393-4BAF-8B87-F3936FFB8C0EQ28546539-2868AAEE-E81A-48A4-AE9F-8B2A6C7AE685Q35800392-D55476A6-8F22-490C-80AD-71B305E1AF19Q36153987-D94D1C5A-95A2-4CB8-99F3-3A33C52BF861Q37745926-55878F98-7E1A-4196-88D1-57C1100E9D93Q38388920-DF220A10-0F4B-4215-9CA4-A0E1DC729DFDQ38651175-18918115-4423-4397-9E7D-7D682B7B9B73Q38703807-1777A52F-B5E4-4FB6-810E-D305B686B28FQ38729534-6756E7CF-7B9A-40B9-A959-3DAA04279254Q38775771-0C72758B-B338-4C82-B225-08FA8FBBB566Q38833040-30CDC9B2-F2CB-4661-82F8-C33BD5DA5150Q43023352-5FE9D58F-1A02-4AF1-854B-100823353004Q47129584-485F2F51-C859-4BF9-9BE7-ABA1B8D30160Q51093729-CB50514C-DD78-4FFA-8639-7D1A9738C2BAQ53421694-EC468FE5-32F8-4459-9152-D71146FEA8B1Q55030699-9BA0B610-08AF-476C-8E94-2AF635410BF8
P2860
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
@en
type
label
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
@en
prefLabel
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
@en
P2093
P356
P1433
P1476
Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth.
@en
P2093
Hidetaka Morinaga
Kazuki Nabeshima
Kunitaka Murase
Makio Mizoguchi
Makito Tanabe
Masatoshi Tanaka
Ryoko Nagaishi
Shinichiro Irie
Takako Kawanami
Takashi Nomiyama
P304
P356
10.2337/DB13-1169
P407
P577
2014-05-30T00:00:00Z